企業概要
IM Cannabis Corp. is engaged in the breeding, cultivation, and supply of medical cannabis products within the markets of Israel and Germany, offering dried flowers and extracts under specific brand names to medical patients. The company operates within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical or therapeutic agents rather than mass-market consumer goods. As of the latest available data, the enterprise holds a market capitalization of $2.21M and reported annual revenue of $54.73M over the trailing twelve months, while the employee count is not disclosed in the provided financial records. These valuation and revenue figures indicate that the company is a micro-cap entity with a significant revenue base relative to its market value, suggesting a potential disconnect between current market pricing and the operational scale of its medical cannabis operations.
財務健全性
The company reported revenue of $54.73M for the trailing twelve months, yet it generated a net income of $-11,319,000 and an EBITDA of $-4,559,000, revealing a substantial gap between top-line generation and profitability that points to a heavy cost structure or significant operating expenses. The free cash flow stands at $-431,875, indicating that the company is currently burning cash rather than generating liquidity, which limits its financial flexibility for organic expansion or debt reduction without external financing. Margin analysis shows a gross margin of 17.7%, which reflects the cost of goods sold relative to sales, while the operating margin of -31.4% and profit margin of -20.7% demonstrate that overhead costs are consuming a large portion of gross profits, resulting in overall losses. The balance sheet presents a challenging picture with cash holdings of $2.73M against total debt of $16.27M, highlighting a leveraged position where liabilities significantly exceed liquid assets. Although the debt-to-equity ratio is not provided, the disparity between cash and debt suggests the company relies on other forms of capital or equity support to service its obligations. Furthermore, the current ratio of 0.67 indicates that current assets are less than current liabilities, signaling potential short-term liquidity constraints that may require careful management of working capital. Return on Equity is not available due to the company's financial structure, while the return on assets stands at -10.9%, reflecting the overall unprofitability of the asset base in generating returns for shareholders.
バリュエーション評価
The P/E Ratio (TTM) is not applicable due to the negative earnings, whereas the forward P/E is listed as -0.27, suggesting that the market does not currently price in a near-term return on equity based on traditional metrics. The price-to-book ratio is -0.78, which indicates that the market values the company at a negative premium relative to its book value, a metric often seen in distressed or loss-making entities where assets may be overvalued on the balance sheet or the company faces significant rebranding needs. Alternative valuation metrics such as the price-to-sales ratio of 0.04 and an EV/EBITDA of -3.48 suggest that the stock is trading at a very low multiple of its sales, reflecting extreme skepticism regarding future profitability or a pricing model that prioritizes sales volume over current earnings quality. Regarding price metrics, the 52-week high is $7.12 and the 52-week low is $0.29, placing the current trading environment within a highly volatile range that has seen a substantial expansion in trading band over the past year. The beta value of 2.27 indicates that the stock price is highly sensitive to market movements, exhibiting volatility that is more than double that of the broader market index.
Growth & Income
Revenue growth over the last year stands at 17.6%, while earnings growth is not applicable due to the lack of positive net income, implying that the company is focusing on expanding its top line rather than achieving immediate profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that any generated earnings are theoretically available for reinvestment into growth initiatives rather than being distributed to shareholders. The absence of dividend payments aligns with the company's current financial stage, where capital is likely required to fund operations, reduce the debt burden of $16.27M, or invest in the cultivation of medical cannabis products in its core markets. Overall, the growth and income profile presents a classic high-risk, high-volatility scenario typical of small-cap biotechnology or specialty manufacturing firms, where capital appreciation must be pursued through stock price appreciation rather than dividend income or consistent earnings growth.